Bains will join his new role effective from 18th September and has stepped down from the board as the independent director with immediate effect

Biocon, an innovation-led global biopharmaceuticals company, has approved the appointment of Peter Bains as the group chief executive officer (CEO), with effect from 18th September 2023. He will be reporting directly to Biocon group chairperson, Kiran Mazumdar-Shaw.

Bains has accordingly stepped down from his role on the Biocon board as an independent director with immediate effect, to assume this strategic executive responsibility.

Kiran Mazumdar-Shaw said, “Biocon is entering a dynamic phase of growth for its 3 core businesses, Biocon Biologics, Biocon Generics and Syngene, and for the Group as a whole. I am delighted to welcome Peter back to the Biocon Group in the role of Group CEO. Siddharth Mittal, CEO & MD Biocon Ltd, Shreehas Tambe, CEO & MD Biocon Biologics Ltd. and Jonathan Hunt, CEO & MD  Syngene International Ltd. will continue to have independent charge of their businesses and will work with Peter to strengthen synergistic strategic leadership at a Group level to maximise the combined value of all 3 businesses."

Bains has a unique fit and profile for the role having both extensive global leadership experience and success across the biopharmaceutical field and a comprehensive understanding of the Biocon Group, having led Syngene for 5 years, taking it through its very successful IPO in 2015.